Literature DB >> 12804124

Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies.

Michael G Aman1, Brett Buican, L Eugene Arnold.   

Abstract

OBJECTIVE: To determine response of low-IQ children with attention deficit hyperactivity disorder (ADHD) symptoms to methylphenidate (MPH).
METHODS: An aggregated analysis was conducted in 90 children with low IQ who received the same dose regimen of MPH in three independent, placebo-controlled studies. Active drug and placebo were given from 2 to 4 weeks each. Outcome measures included teacher and parent ratings on standardized behavior scales (mean n = 84), performance on computer-controlled cognitive-motor tests (n = 62), and measures of cardiovascular response (n = 85).
RESULTS: Both teachers and parents rated the children consistently as being improved on subscales assessing attention, overactivity, and conduct problems. Some 44% of the subjects showed at least a 30% reduction compared with placebo on teacher ratings. MPH improved accuracy on several cognitive tests, response speed was increased on some, and seat activity declined for one of three tests; heart rate was mildly increased (3.9 beats/minute) with MPH. Analyses of IQ and mental age as moderator variables suggested that lower functional level (especially lower IQ) may be associated with a less favorable response to MPH.
CONCLUSIONS: Children with low IQ and ADHD clearly respond to MPH, but their rate of beneficial response appears to be well under that of normal-IQ children and more varied. Different attentional mechanisms may moderate response to psychostimulants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804124     DOI: 10.1089/104454603321666171

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  30 in total

1.  Children with psychiatric disorders and learning disabilities.

Authors:  Emily Simonoff
Journal:  BMJ       Date:  2005-04-02

2.  Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Authors:  L Eugene Arnold; Michael G Aman; Jill Hollway; Elizabeth Hurt; Bethany Bates; Xiaobai Li; Cristan Farmer; Rene Anand; Susan Thompson; Yaser Ramadan; Craig Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

3.  ADHD symptom subtypes in children with pervasive developmental disorder.

Authors:  Kenneth D Gadow; Carla J DeVincent; John Pomeroy
Journal:  J Autism Dev Disord       Date:  2006-02

4.  Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan
Journal:  J Pediatr Psychol       Date:  2009-05-22

Review 5.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

6.  Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism.

Authors:  Stephen Bent; Robert L Hendren; Tara Zandi; Kiely Law; Jae-Eun Choi; Felicia Widjaja; Luther Kalb; Jay Nestle; Paul Law
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-03-12       Impact factor: 8.829

Review 7.  The use of psychostimulants in pervasive developmental disorders.

Authors:  Patricia Karen Abanilla; Greg A Hannahs; Robyn Wechsler; Raul R Silva
Journal:  Psychiatr Q       Date:  2005

8.  Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

Authors:  Luigi Mazzone; Laura Reale; Valeria Mannino; Mariadonatella Cocuzza; Benedetto Vitiello
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 9.  Attention deficits, Attention-Deficit Hyperactivity Disorder, and intellectual disabilities.

Authors:  Curtis K Deutsch; William V Dube; William J McIlvane
Journal:  Dev Disabil Res Rev       Date:  2008

10.  Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.

Authors:  Jaswinder K Ghuman; Michael G Aman; Luc Lecavalier; Mark A Riddle; Alan Gelenberg; Ron Wright; Sydney Rice; Harinder S Ghuman; Carolyn Fort
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-08       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.